Alemtuzumab (Anti-CD52) Biosimilar In Vivo Antibody

Product Name:	Alemtuzumab (Anti-CD52) Biosimilar In Vivo Antibody
Product Code:	IVMB0224
Clone:	Campath-1H
Protein:	CD52
Product Type:	Biosimilar Recombinant Human Monoclonal Antibody
Synonyms:	HE5, CDW52, EDDM5 CDW52, Cambridge pathology 1 antigen
Isotype:	Human IgG1κ
Reactivity:	Human/Rhesus Monkey/Cynomolgus Monkey
Immunogen:	Human lymphocytes.
Applications:	CyTOF®, ELISA, FA, FC, IHC FF, IHC FFPE, WB
Formulation:	This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Endotoxin Level:	< 1.0 EU/mg as determined by the LAL method
Purity:	>95% by SDS-PAGE and HPLC
Preparation:	Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:	Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Applications:	CyTOF®, ELISA, FA, FC, IHC FF, IHC FFPE, WB
Recommended Usage:	FC The suggested concentration for Alemtuzumab biosimilar antibody for staining cells in flow cytometry is ≤ 0.25 µg per 10⁶ in a volume of 100 µl. Titration of the reagent is recommended for optimal performance for each application.
Reactivity:	Human/Rhesus Monkey/Cynomolgus Monkey

Specificity:	This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Alemtuzumab. Clone Campath-1H recognizes human CD52. This product is for research use only.
Antigen Distribution:	CD52 is primarily expressed on the surface of mature lymphocytes. Additionally, CD52 is present on most lymphoid derived malignancies. However, variable expression on Myeloma cells should be noted.
Immunogen:	Human lymphocytes.
Concentration:	≥ 5.0 mg/ml
Endotoxin Level:	< 1.0 EU/mg as determined by the LAL method
Purity:	>95% by SDS-PAGE and HPLC
Formulation:	This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Preparation:	Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:	Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Clone Campath-1H is a monoclonal antibody that specifically binds to CD52, a protein present on the surface of mature lymphocytes. However, this protein is not present on the stem cells that generated these lymphocytes. Alemtuzumab is targets and destroys mature lymphocytes containing CD-52, and is used to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis. Anti-Human CD52 (Alemtuzumab) utilizes the same variable regions from the therapeutic antibody Alemtuzumab making it ideal for research projects.

Protein:

CD52